Lessons from negative phase 3 trials in rheumatoid arthritis anno 2023

Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis

(2023) Andreas Kerschbaumer et al.   ANNALS OF THE RHEUMATIC DISEASES

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

(2022) Steven R. Ytterberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis

(2022) Andreas Kerschbaumer et al.   ANNALS OF THE RHEUMATIC DISEASES

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial

(2021) René Westhovens et al.   ANNALS OF THE RHEUMATIC DISEASES

Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial

(2021) Veerle Stouten et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

(2020) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Granulocyte-macrophage colony stimulating factor as an indirect mediator of nociceptor activation and pain

(2020) Damini Tewari et al.   JOURNAL OF NEUROSCIENCE

Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach

(2020) Andrew R. Melville et al.   DRUGS

Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology

(2020) Andreas Kerschbaumer et al.   NATURE MEDICINE

Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial

(2020) Rene Westhovens et al.   RHEUMATOLOGY

Placebo response in rheumatoid arthritis clinical trials

(2019) Katie Bechman et al.   JOURNAL OF RHEUMATOLOGY

Patient reported outcome data from the Care in Early Rheumatoid Arthritis trial: Opportunities for broadening the scope of treating to target

(2019) Kristien Van der Elst et al.   ARTHRITIS CARE & RESEARCH

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis

(2017) Michael E. Weinblatt et al.   Arthritis & Rheumatology

Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment

(2016) Iris M. Markusse et al.   ANNALS OF INTERNAL MEDICINE

Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials

(2016) M. Boers et al.   JOURNAL OF RHEUMATOLOGY

Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis

(2014) D E A Greven et al.   ANNALS OF THE RHEUMATIC DISEASES

Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial

(2011) R. F. van Vollenhoven et al.   ARTHRITIS AND RHEUMATISM